Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 21

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 21
---
 consideration for the Selling Shareholder entering into the Purchase Agreement. In the event that we fail to pay the Commitment
Fee when due, we shall have the right, at our discretion, to issue Depositary Shares representing the value of the Commitment Fee in aggregate,
valued at the closing sale price for the Depositary Shares on Nasdaq on the trading day immediately prior to the date of execution of
the Purchase Agreement, to release us of our liability to pay the Commitment Fee as a liquidated sum. To the extent Commitment Shares
are issued in lieu of paying the Commitment Fee, we intend to issue up to 612,500 Depositary Shares (equal to 1.75% of the Commitment
Amount) upfront, with the remainder paid upon each Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, as the case may be, until
such amount is paid in full.

We have also agreed to pay
to the Selling Shareholder $35,000 in cash as reimbursement for the reasonable, out-of-pocket expenses incurred by the Selling Shareholder,
including the legal fees and disbursements of the Selling Shareholder’s legal counsel, in connection with its due diligence investigation
of our company and in connection with the preparation, negotiation and execution of the Purchase Agreement.

Conditions Precedent to Commencement

Our right to commence delivering
Purchase Notices under the Purchase Agreement and the Selling Shareholder’s obligation to accept a Fixed Purchase Notice, VWAP Purchase
Notice or Additional VWAP Purchase Notice, are subject to the initial satisfaction, at the Commencement Date, of the conditions precedent
thereto set forth in the Purchase Agreement, which conditions include, among others, the following:

| · | the accuracy in all material respects of our representations and warranties included in the Purchase Agreement; |

| · | us having performed, satisfied and complied in all material respects with all covenants, agreements and                                
 conditions required by the Purchase Agreement and the Registration Rights Agreement to be performed, satisfied or complied with by us; |

| 14 |

| · | the absence of any material misstatement or omission in the registration statement that includes this 
 prospectus;                                                                                           |

| · | this prospectus, in final form, and all reports, schedules, registrations, forms, statements, information                                 
 and other documents required to have been filed by us with the SEC pursuant to the reporting requirements of the Exchange Act having been 
 so filed;                                                                                                                                 |

| · | the Depositary Shares not having been suspended